Ali Amid

Investigator, CHEO Research Institute

Dr. Amid is a pediatric hematologist/oncologist at CHEO and an assistant professor at the Department of Pediatrics at the University of Ottawa. He received his medical degree from the Tehran University of Medical Sciences and completed his pediatric residency at the University of Calgary followed by his pediatric hematology/oncology fellowship at the University of Ottawa and University of Toronto. Dr Amid subsequently completed a clinical and research fellowship in hemoglobinopathies and iron overload disorders at the Hospital for Sick Children (SickKids) in Toronto.

At CHEO he is the physician lead for the Thrombosis Clinic as well as the Thalassemia and Iron Overload Clinic. Dr Amid’s area of clinical and research interest is in the field of thalassemia, iron overload, and thrombosis, and he collaborates with other researchers on a national and international level. He is the principal investigator of an international collaborative research study in thalassemia (IntercontinenTHAL study), and a member of the Hemoglobin Bart’s Hydrops Fetalis Consortium and the International Pediatric Thrombosis Network.  His research team at CHEO participates in numerous academic and registered clinical trials. Dr. Amid has been the recipient of many research and clinical awards (e.g. Thalassemia Foundation of Canada Research Grant) and his research has been published in leading hematology journals like Blood, Lancet Haematology and Haematologica.

Research Projects

  1. Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study


    Massive or submassive pulmonary embolism led to higher rates of unfavourable outcomes than non-massive pulmonary embolism in children. Further adaptations of PESI and sPESI are required to improve their clinical usefulness in paediatric patients.

  2. Iron Overload In Transfusion-Dependent Survivors Of Hemoglobin Bart’s Hydrops Fetalis


    While homozygous α0-thalassemia is currently considered a rare disease, its prevalence is likely to rise given the high α0-thalassemia gene carrier rates in Southeast Asia coupled with recent advances in fetal medicine that is delivering improved access to intra-uterine transfusions.